Medicines Source unknown
Dealstreet

Rajani, Vertices act on La Renon Healthcare investment in Enaltec Labs

The deal values Enaltec at a post-money valuation of ₹180-200 crore.

Bar & Bench

La Renon Healthcare, a pharmaceutical company has acquired 51% stake in Enaltec Labs. The deal values Enaltec at a post-money valuation of ₹180-200 crore.

Rajani Associates advised La Renon Healthcare and the team included:

  • Transation Team - Poorvi Sanjanwala (Partner), Nishtha Mehta (Senior Associate), Kashmira Bakliwal (Senior Associate) and Rutvik Rajagopal (Associate)

  • Diligence Team - Ankur Singhania (Partner), Kashmira Bakliwal, Rohan Gajaria and Rutvik Rajagopal.

Vertices Partners advised Enaltec Labs with a team led by Partners Amit Manubarwala and Vishal Mehta.

Managing Partner, Vinayak Burman provided strategic inputs.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

We would be mad not to take advantage of the Indian market liberalisation: Stephen Moriarty KC

Win for PVR, BookMyShow as Bombay High Court allows convenience fees on online movie tickets

Delhi High Court stays release of Udaipur Files movie, directs Centre to take final call on certification

Delhi High Court restrains Kuku FM from streaming 5 shows after Pocket FM alleges IP violation

Rajasthan court summons Drishti IAS founder Vikas Divyakirti for derogatory remarks against judiciary

SCROLL FOR NEXT